These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36463731)

  • 1. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.
    Schipper LJ; Samsom KG; Snaebjornsson P; Battaglia T; Bosch LJW; Lalezari F; Priestley P; Shale C; van den Broek AJ; Jacobs N; Roepman P; van der Hoeven JJM; Steeghs N; Vollebergh MA; Marchetti S; Cuppen E; Meijer GA; Voest EE; Monkhorst K
    ESMO Open; 2022 Dec; 7(6):100611. PubMed ID: 36463731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence.
    Zhao Y; Pan Z; Namburi S; Pattison A; Posner A; Balachander S; Paisie CA; Reddi HV; Rueter J; Gill AJ; Fox S; Raghav KPS; Flynn WF; Tothill RW; Li S; Karuturi RKM; George J
    EBioMedicine; 2020 Nov; 61():103030. PubMed ID: 33039710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE).
    Samsom KG; Bosch LJW; Schipper LJ; Roepman P; de Bruijn E; Hoes LR; Riethorst I; Schoenmaker L; van der Kolk LE; Retèl VP; Frederix GWJ; Buffart TE; van der Hoeven JJM; Voest EE; Cuppen E; Monkhorst K; Meijer GA
    BMC Med Genomics; 2020 Nov; 13(1):169. PubMed ID: 33167975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.
    Posner A; Sivakumaran T; Pattison A; Etemadmoghadam D; Thio N; Wood C; Fisher K; Webb S; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Fellowes A; Fox SB; Hicks RJ; Schofield P; Bowtell D; Prall OWJ; Tothill RW; Mileshkin L
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice.
    Samsom KG; Schipper LJ; Roepman P; Bosch LJ; Lalezari F; Klompenhouwer EG; de Langen AJ; Buffart TE; Riethorst I; Schoenmaker L; Schout D; van der Noort V; van den Berg JG; de Bruijn E; van der Hoeven JJ; van Snellenberg H; van der Kolk LE; Cuppen E; Voest EE; Meijer GA; Monkhorst K
    J Pathol; 2022 Oct; 258(2):179-188. PubMed ID: 35792649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Whole genome sequencing to find the primary tumour in cancer of unknown primary origin].
    van der Hoeven JJM; Monkhorst K; van de Wouw AJ; Roepman P
    Ned Tijdschr Geneeskd; 2023 Sep; 167():. PubMed ID: 37823879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Tissue of Origin and Guided Therapeutic Applications in Cancers of Unknown Primary Using Deep Learning and RNA Sequencing (TransCUPtomics).
    Vibert J; Pierron G; Benoist C; Gruel N; Guillemot D; Vincent-Salomon A; Le Tourneau C; Livartowski A; Mariani O; Baulande S; Bidard FC; Delattre O; Waterfall JJ; Watson S
    J Mol Diagn; 2021 Oct; 23(10):1380-1392. PubMed ID: 34325056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TOD-CUP: a gene expression rank-based majority vote algorithm for tissue origin diagnosis of cancers of unknown primary.
    Shen Y; Chu Q; Yin X; He Y; Bai P; Wang Y; Fang W; Timko MP; Fan L; Jiang W
    Brief Bioinform; 2021 Mar; 22(2):2106-2118. PubMed ID: 32266390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
    Dermawan JK; Rubin BP
    Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of a novel microarray-based diagnostic test for cancer of unknown primary.
    van Laar RK; Ma XJ; de Jong D; Wehkamp D; Floore AN; Warmoes MO; Simon I; Wang W; Erlander M; van't Veer LJ; Glas AM
    Int J Cancer; 2009 Sep; 125(6):1390-7. PubMed ID: 19536816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer.
    Economopoulou P; Mountzios G; Pavlidis N; Pentheroudakis G
    Cancer Treat Rev; 2015 Jul; 41(7):598-604. PubMed ID: 26033502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary.
    Chen K; Zhang F; Yu X; Huang Z; Gong L; Xu Y; Li H; Yu S; Fan Y
    J Transl Med; 2022 Apr; 20(1):158. PubMed ID: 35382836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
    Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
    J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary.
    Fusco MJ; Knepper TC; Balliu J; Del Cueto A; Laborde JM; Hooda SM; Brohl AS; Bui MM; Hicks JK
    Oncologist; 2022 Feb; 27(1):e9-e17. PubMed ID: 35305098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six-year experience of Australia's first dedicated cancer of unknown primary clinic.
    van Mourik A; Tonkin-Hill G; O'Farrell J; Waller S; Tan L; Tothill RW; Bowtell D; Fox S; Fellowes A; Fedele C; Schofield P; Sivakumaran T; Wong HL; Mileshkin L
    Br J Cancer; 2023 Aug; 129(2):301-308. PubMed ID: 37225894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.
    Hainsworth JD; Greco FA
    Virchows Arch; 2014 Apr; 464(4):393-402. PubMed ID: 24487792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic characterisation of molecular targets in carcinoma of unknown primary.
    Clynick B; Dessauvagie B; Sterrett G; Harvey NT; Allcock RJN; Saunders C; Erber W; Meehan K
    J Transl Med; 2018 Jul; 16(1):185. PubMed ID: 29973234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review on Cancer of Unknown Primary Origin: The Role of Molecular Biomarkers in the Identification of Unknown Primary Origin.
    Yan N; Zhang Y; Guo X; Yuan D; Tian G; Yang J
    Methods Mol Biol; 2020; 2204():109-119. PubMed ID: 32710319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of various techniques/platforms with critical evaluation of each.
    Agwa E; Ma PC
    Curr Treat Options Oncol; 2013 Dec; 14(4):623-33. PubMed ID: 24243164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
    Hayashi H; Takiguchi Y; Minami H; Akiyoshi K; Segawa Y; Ueda H; Iwamoto Y; Kondoh C; Matsumoto K; Takahashi S; Yasui H; Sawa T; Onozawa Y; Chiba Y; Togashi Y; Fujita Y; Sakai K; Tomida S; Nishio K; Nakagawa K
    JAMA Oncol; 2020 Dec; 6(12):1931-1938. PubMed ID: 33057591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.